Search

Your search keyword '"Al-Hashmi, H. A."' showing total 14 results
Start Over Author "Al-Hashmi, H. A."
14 results on '"Al-Hashmi, H. A."'

1. Risk Assessment for Newly Diagnosed Fit Young Patients with Multiple Myeloma in the Era of Novel Treatment Modalities: Should There Be Additional Factors Taken into Consideration??

Author

Kaloyannidis P, Abdulla F, Mutahar E, Al Hashim H, Al Harbi S, Estanislao A, and Al Hashmi H

Subjects
multiple myeloma, high risk multiple myeloma, multiple myeloma risk assessment, young newly diagnosed multiple myeloma patients, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Panayotis Kaloyannidis, Fatema Abdulla, Enas Mutahar, Haidar Al Hashim, Salman Al Harbi, Analie Estanislao, Hani Al Hashmi Adult Hematology and Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi ArabiaCorrespondence: Panayotis Kaloyannidis, Adults Hematology and Stem Cell Transplantation Department, King Fahad Specialist Hospital, Ammar Bin Thabit Street, Al Muraikabat, Dammam, 31444, Saudi Arabia, Tel +966-330-1174, Fax +966 13 844-2222, Email pkaloyannidis@yahoo.gr; Kalogiannidi.panagiotis@kfsh.med.saIntroduction: The optimal treatment for young patients with high-risk newly diagnosed multiple myeloma (NDMM) remains a challenge.Methods: We retrospectively evaluated 58 NDMM patients younger than 55 years treated in our center from 2010 to 2021 with the current recommended protocols.Results: After a median follow-up of 48 months, median overall survival (OS) was not reached; however, approximately 25% of them died within 4 years after diagnosis. Advanced disease stage, presence of extramedullary disease, elevated LDH, and less than very good remission before autologous hematopoietic stem-cell transplantation adversely affected patient survival. Based on these factors, we created a risk-assessment scoring system that sufficiently discriminated young NDMM patients at risk of poor outcome. The 4-year OS was superior for patients with zero to two factors to those with three to five factors (86% vs 44%, p< 0.001).Conclusion: The proposed scoring system could be reliably used at diagnosis and at interim disease evaluation in aiming for personalized treatment for young NDMM patients.Keywords: multiple myeloma, high-risk multiple myeloma, multiple myeloma risk assessment, young newly diagnosed multiple myeloma patients

Published
2022

6. Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends

Author

Baldomero, H, Aljurf, M, Zaidi, SZA, Hashmi, SK, Ghavamzadeh, A, Elhaddad, A, Hamladji, R-M, Ahmed, P, Torjemane, L, Abboud, M, Tbakhi, A, Khabori, MA, El Quessar, A, Bazuaye, N, Bekadja, MA, Adil, S, Fahmy, O, Ramzi, M, Ibrahim, A, Alseraihy, A, Ben Abdejalil, N, Sarhan, M, Huneini, MA, Mahmal, L, ElSolh, H, Hussain, F, Nassar, A, Al-Hashmi, H, Hamidieh, AA, Pasquini, M, Kodera, Y, Kröger, N, Mohty, M, Jaimovich, G, Rolon, JM, Paulson, K, Greinix, H, Weisdorf, D, Horowitz, M, Nunez, J, Gratwohl, A, Passweg, J, Koh, M, Szer, J, Niederwieser, D, Novitzky, N, and East-Mediterranean (EMBMT) and African (AfBMT) Blood and Marrow

Subjects
surgical procedures, operative, immune system diseases
Abstract

Hematopoietic Stem Cell Transplantation (HSCT) activity was evaluated in the African (AFR)/EMRO region and compared to the global activity for the years 2006-2013. Data were obtained from 1570 teams in the 6 WHO continental regions. Of these, 29 (1.85%) of all teams were active in 12 of the 68 AFR/EMRO countries. They reported 2.331 (3.3%) of the worldwide 71.036 HSCT, and a transplant rate of 32.8 (TR; HSCT/10 million inhabitants; worldwide 128.5). This reflects still the lowest regional TR despite an increase of 90% since 2006. HSCT activity in AFR/EMRO countries was characterized by a higher use of allogeneic compared to autologous HSCT, an almost exclusive use of family donors, including haploidentical family donors. These findings contrast with the prevalence of autologous over allogeneic HSCT, and a higher frequency of unrelated HSCT in other parts of the world. Of note, the increase by 200% in HSCT for hemoglobinopathies from 2006 to 2013 (72 per year) in the AFR/EMRO region. This reflects the specific role of HSCT for these disease categories with high prevalence and incidence in the AFR/EMRO region. This report provides information for the competent authorities to foster adequate infrastructure. It urges transplant organization to optimize their cooperation.

Published
2019

7. Histological patterns and clinical characteristics of metastatic gastric adenocarcinoma, single institutional experience in the eastern province of Saudi Arabia

Author

Bukhari, N., primary, Taha, W., additional, Zahralliyali, A., additional, Shahrani, S., additional, AlSelwi, W., additional, AlSowayigh, A., additional, AlAbdulhadi, D., additional, Ibnshamsah, F., additional, Rahal, M., additional, Halawani, H., additional, Al-Saif, O., additional, Mashhour, M., additional, Al-Hashmi, H., additional, Latif, M., additional, and Azam, F., additional

Published
2019
Full Text
View/download PDF

8. A Young Patient with Refractory Multiple Myeloma and Dialysis-Dependent Renal Failure has been Cured by Non-Cryopreserved Autologous Stem Cell Transplantation Followed by Live-Related Kidney Transplantation

Author

Akkari K, Abduljalil O, AlBahrani At, Bacal J, AlJatham A, Kalogiannidis P, Alshaibani E, Kawari M, Estanislao A, Mokhtar N, Al-Anazi Ka, and Al-Hashmi H

Subjects
medicine.medical_specialty, business.industry, medicine.medical_treatment, Hematopoietic stem cell transplantation, medicine.disease, Surgery, Transplantation, Maintenance therapy, medicine, Hemodialysis, Complication, business, Kidney transplantation, Dialysis, Multiple myeloma
Abstract

Management of patients with multiple myeloma having dialysis-dependent renal failure, particularly if the disease is refractory to several lines of therapy, is a difficult task. Cure of such patients represents a real challenge to the treating team. In late November 2009, the diagnosis of multiple myeloma was made in a young patient who had been receiving regular hemodialysis for end-stage renal disease. His myeloma was refractory to four lines of therapy and it responded partially to the fifth line of treatment. Thereafter, the patient received a noncryopreserved autologous hematopoietic stem cell transplantation which brought his myeloma under more optimal control. One year later, he received live-related kidney transplantation. During his subsequent follow-up for fifty four months post-renal transplantation at King Fahad Specialist Hospital in Dammam, Saudi Arabia, no complication has been encountered. As the case is complicated, the literature review will be detailed in order to discuss the various aspects related to care of the patient presented.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results